Safety and Efficacy Study in the Treatment of Pediatric Crohn's Disease

Stopped early · Phase 1/Phase 2

Conditions studied: Crohn Disease

In brief

The purpose of this study is to observe pediatric Crohn's Disease response to sargramostim in patients with or without steroid therapy at two possible dosage levels.

Key facts

Study ID

NCT00206661

Run by

Genzyme, a Sanofi Company

People needed

22

Starts

2004-12-01

Expected to finish

2006-12-01

Last updated by the study team

2013-12-04

Who can join

Age: 6 and older, up to 16. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a parent or guardian able to provide written informed consent
• Be able to provide verbal or written assent depending on age
• Age 6 to 16 years
• Have confirmed diagnosis of Crohn's Disease at study time of study entry based on radiologic, endoscopic, or histologic evaluations
• Have a PCDAI score >/= 30 points
• Have a negative serum pregnancy test within 7 days prior to receiving the first dose of sargramostim in female patients who, in the opinion of the investigator, are sexually active and of childbearing potential
• Be able to self-inject sargramostim or have a designee who can do so
• Available documentations of weight from 4 to 6 months prior to study entry

You may not qualify if…

• Existing colostomy or ileostomy
• Immediate need of GI surgery for active GI bleeding, peritonitis, intestinal obstruction, or intra-abdominal or perianal abscess requiring surgical drainage
• GI surgery within 3 month prior to receiving the first dose of sargramostim
• Symptoms of bowel obstruction or confirmed evidence of a clinically significant stricture within the last 6 month that has not been surgically corrected
• Use of any of the following medications within 4 weeks prior to receiving the first dose of study drug: 6 mercaptopurine, azathioprine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, cyclosporine, or thalidomide
• Use of licensed/registered and/or experimental anti-tumor necrosis factor (TNF) therapy such as infliximab or adalimumab within 8 weeks prior to first dose of sargramostim
• Use of any investigational drug within 4 weeks or 5 half-lives (whichever is greater) prior to receiving the first dose of sargramostim
• Concurrent use of corticosteroid therapy for Crohn's Disease, which exceeds a dose of 60 mg/day (or equivalent) of prednisone
• Inability to comply with protocol requirements or provide informed consent
• Presence of clinically important comorbid condition(s) unrelated to Crohn's Disease
• Prior use of recombinant human GM-CSF (sargramostim or molgramostim) or granulocyte colony-stimulating factor (G-CSF; filgrastim or pegfilgrastim)
• Current use of nutritional therapy (i.e., tube feeding or elemental/polymeric diet) which provides > 50% of daily caloric intake

Where it is running

• Study site — San Francisco, California, United States
• Study site — Atlanta, Georgia, United States
• Study site — New Orleans, Louisiana, United States
• Study site — Boston, Massachusetts, United States
• Study site — Morristown, New Jersey, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.